Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Tabrecta™ works as a Mesenchymal-epithelial transition (MET) inhibitor. Credit: Novartis Pharmaceuticals Corporation.